Table 3.
Multivariable Linear Regression Models for Short Form-12 Components and Cancer Treatment Distress in YA Patients
| Short Form-12 Physical Component Score | Short Form-12 Mental Component Score | Cancer and Treatment Distress | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Variable | Parameter Estimate | 95% CI | P-Value | Parameter Estimate | 95% CI | P-Value | Parameter Estimate | 95% CI | P-Value |
| Age at Baseline Survey (per 1 yr increase) | −0.107 | (−0.160,−0.053) | <0.0001 | 0.014 | (−0.034,0.062) | 0.56 | 0.00005 | (−0.003,0.003) | 0.98 |
| Sex (Femal e vs. Male) | −0.382 | (−1.702,0.939) | 0.57 | −0.686 | (−1.874,0.503) | 0.26 | 0.057 | (−0.016,0.129) | 0.13 |
| Race (NonWhite* vs. White) | 0.206 | (−2.566,2.977) | 0.88 | 1.435 | (−1.059,3.929) | 0.26 | 0.071 | (−0.081,0.224) | 0.36 |
| Ethnicity (Non-Hispanic vs. Hispanic) | −0.692 | (−4.006,2.622) | 0.68 | 0.793 | (−2.189,3.775) | 0.6 | −0.111 | (−0.296,0.075) | 0.24 |
| Total Body Irradiation (No vs. Yes) | −1.189 | (−2.913,0.535) | 0.18 | −0.374 | (−1.926,1.177) | 0.64 | 0.082 | (−0.013,0.177) | 0.09 |
| Transplant Group | |||||||||
| Allogeneic no cGVHD | - | - | - | - | - | - | - | - | - |
| Allogeneic with cGVHD | −3.157 | (−5.956,0.359) | 0.0271 | −2.791 | (−5.309,−0.273) | 0.0299 | −0.0004 | (−0.155, 0.154) | 0.996 |
| Autologous | 1.061 | (−1.775,3.898) | 0.46 | −0.378 | (−2.930,2.175) | 0.77 | −0.203 | (−0.360,−0.047) | 0.0107 |
| Years Since HCT (per 1 yr increase) | 0.181 | (−0.124,0.487) | 0.24 | 0.028 | (−0.247, 0303) | 0.84 | −0.023 | (0.040, 0.006) | 0.0082 |
| Health Self-Efficacy (per 1 point) | 9.018 | (7.679,10.358) | <0.0001 | 11.95 | (10.745,13.155) | <0.0001 | −0.615 | (−0.688,−0.541) | <0.0001 |
Note: CI: Confidence Interval; Short Form-12 (higher value is better functioning); Cancer and Treatment-Related (lower number indicates less distress); HCT: Hematopoetic Cell Transplant;
*
includes Asian, Black, Multiple Races, and Native American